Erin VanDyke on Why They Do In-person Site Visits for NBCA Centers of Excellence Designation!
Erin VanDyke, Vice President of NBCA Centers of Excellence, shared on LinkedIn:
”“Why do you do in-person site visits for COE designation?”
It’s a question I get asked often — and honestly, it’s one of my favorite parts of the process to talk about.
At National Blood Clot Alliance, we believe that achieving a Center of Excellence designation should reflect more than the strength of one service line.
It should represent a hospital-wide commitment to improving every aspect of VTE prevention, diagnosis, treatment, follow-up, and community awareness.
That’s why the site visit matters so much.
Being there in person allows us to see and feel the culture — how the team communicates, how barriers are approached, and how deeply VTE awareness is woven into the organization.
It gives us a chance to meet the people who make the work happen — from the physicians and APPs to the nurses, pharmacists, and administrators — and to have honest conversations about what’s working, what’s not, and where we can help.
The goal isn’t just to evaluate readiness for designation; it’s to partner in building something sustainable.
To use objective data to refine pathways, strengthen careflows, and ultimately deliver the best possible outcomes for patients.
Because for us, the COE designation isn’t a finish line — it’s the beginning of an ongoing collaboration to grow, evolve, and raise the bar for VTE care together.”
Stay updated with Hemostasis Today.
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25
-
Jan 7, 2026, 05:04Heghine Khachatryan on VWD: A Landmark in the History of Hematology
-
Jan 6, 2026, 13:39JAMA Neurology: No Added Benefit of Dual Therapy After Ischemic Stroke in Case of AFib
-
Jan 6, 2026, 10:10This is Fantastic: Shirley D’Sa on Transfusion-Free Christmas Milestone for 𝛃-Thalassaemia Patient at UCLH
-
Jan 6, 2026, 09:53Hamideh Yadegari: Coagulation–Inflammation Crosstalk: Mechanisms, Pathways, and Clinical Implications